G-protein coupled receptor kinases (GRKs) constitute a serine/ threonine kinase family playing a major role in agonist-induced phosphorylation and desensitization of G-protein coupled receptors. Recently, GRK2 and GRK5 have been demonstrated to phosphorylate >-synuclein (Ser129) and other synuclein isoforms. We studied colocalization of GRK2, GRK5, >-synuclein, and tau in neurodegenerative disorders characterized by fibrillary tau inclusions and/or >-synuclein-enriched Lewy bodies. We found that Lewy bodies were negative for both GRK2 and GRK5 in Lewy body disease (LBD) and LBD mixed with Alzheimer disease (AD + LBD). Instead, GRK2 but not GRK5 colocalized with 40% to 50% of neurofibrillary tangles in AD + LBD and AD brains. In disorders with less prominent >-synucleinopathy, neuronal and glial fibrillary tau deposits known to contain distinct subsets of tau isoforms were also positive for GRK2. These deposits included tufted astrocytes and coiled bodies in progressive supranuclear palsy, astrocytic plaques in corticobasal degeneration, and Pick bodies in Pick disease. In addition, paired helical filaments isolated from AD and AD + LBD brains were found to immunogold-label for GRK2, suggesting that GRK2 could be a potential tau kinase associated with fibrillary tau. Our studies indicate that GRK2 is a novel component of neuronal and glial fibrillary tau deposits with no preference in tau isoform binding. GRK2 may play a role in hyperphosphorylation of tau in tauopathies.
INTRODUCTION
Traditionally, G proteins are signaling molecules of G-protein coupled receptors (GPCRs), which respond to ligands such as neurotransmitters (e.g. GABA) or biologically active amines (e.g. dopamine). In G-protein signaling, important regulatory proteins are G-protein coupled receptor kinases (GRKs) and A-arrestins, which desensitize GPCRs and promote receptor recycling (1, 2) . Recent studies showed that recycling of GPCRs responsive to insulin are mediated by Akt (3) . GRKs are serine/threonine kinases initially identified by their ability to phosphorylate agonist-activated GPCRs (4), but their physiological role is poorly understood. There are 7 known mammalian GRKs separated into 3 subgroups depending on the molecular structure: 1) GRK1 and GRK7; 2) GRK2 and GRK3, which compose the A-adrenergic receptor kinase subfamily; and 3) GRK4, GRK5, and GRK6, which compose the GRK4 subfamily. Only 4 members (GRK2, -3, -5, and -6) appear to be expressed in a wide range of cell types (4) . The most thoroughly characterized member of the GRK family is GRK2, which binds to and phosphorylates a large number of GPCRs (5) . Until recently, GPCRs were considered to be the only natural substrates for GRKs. Nonreceptor substrates phosphorylated by GRK2 were identified as rhodopsin (6) , A2-adrenergic receptors (7), synucleins (8) , and A-tubulin (9) . Among the synuclein family consisting of >-, A-, F-synuclein, and synoretin, GRK2 preferentially phosphorylates the >-and A-isoforms, whereas GRK5 prefers >-synuclein as a substrate (8) .
>-synuclein is a natively unfolded presynaptic protein composed of 140 amino acids regulating synaptic function and plasticity. Abnormal deposits of fibrillary >-synuclein are found in brains of patients with Lewy body disease (LBD), including Parkinson disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy, collectively referred to as synucleinopathies. These deposits are known as Lewy bodies, Lewy neurites (10) , and glial cytoplasmic inclusions (11) . They all contain >-synuclein abnormally phosphorylated at Ser129, a phospho epitope associated with the fibrillary form of >-synuclein (12, 13) . Kinases phosphorylating >-synuclein were identified as GRK2, GRK5 (8) , and casein kinases 1 and 2 (14) . Among them, GRK2 phosphorylates Ser129 of >-synuclein in vivo and enhances >-synuclein toxicity in Drosophila double transfected with GRK2 and >-synuclein (15) .
Like synuclein, hyperphosphorylated forms of microtubule-associated protein tau accumulate in pathologic brain inclusions in Alzheimer disease (AD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), Pick disease (PiD), and other neurodegenerative disorders referred to as tauopathies. These inclusions contain a characteristic fibrillary form of tau found in both neurons and glia. Normal adult tau consists of 6 tau isoforms generated by alternative gene splicing (16) . Abnormal tau aggregates, however, may contain distinct tau isoforms. In PiD, tau lesions are preferentially enriched in tau isoforms expressing 3 repeats in the microtubule-binding domain, whereas in CBD, tau lesions contain 4 repeat tau isoforms. Most recognized neuronal inclusions are neurofibrillary tangles (NFTs) in AD composed of paired helical filaments (PHFs) containing all 6 tau isoforms. Although synucleinopathies and tauopathies are distinct neurodegenerative diseases, they frequently have overlapping pathologies. For example, LBD, CBD, PSP, PiD, and AD, including AD + LBD, demonstrate tau pathology in the presence of Lewy bodies (17) . Lewy bodies are found in approximately 60% of AD cases (18) . Although tau inclusions like NFTs contain no synuclein (19) , colocalization of >-synuclein and tau can be observed in other inclusions within one neuron or within one inclusion (20) . Colocalization of >-synuclein and hyperphosphorylated tau has been shown in Lewy bodies in PD and DLB (21, 22) , Lewy bodies in PSP (23, 24) , and Pick bodies in PiD (24, 25) .
Evidence of GRK involvement in the pathogenesis of synucleinopathies and/or tauopathies is rather sketchy. Therefore, in our present studies, we explored localization of GRK2 and GRK5 in abnormal deposits containing >-synuclein and/or fibrillary tau. For comparison, in selected lesions, we also studied Akt, one of the several kinases reported to localize with neurofibrillary pathology (26, 27) and involved in tau phosphorylation (28) . Akt was used as a reference in preferential staining of fibrillary tau but not >-synuclein inclusions.
Our goal was to demonstrate whether GRK2 and GRK5 associate exclusively with one type of lesion and whether this could be relevant to the pathophysiology of synucleinopathies and/or tauopathies.
MATERIALS AND METHODS

Brain Cases
Human brain samples used in our studies are listed in Table 1 . Autopsy brain material was obtained from the brain bank of the Department of Neuropathology, Mayo Clinic, Jacksonville, FL, and from the brain bank of the Department of Pathology (Neuropathology), Montefiore Medical Center, Bronx, NY. Using autopsy material including human fetal brain tissue obtained from elective termination of pregnancies (19 weeks of gestation) has been approved by Institutional Review Board of the Mount Sinai School of Medicine. AD cases underwent neuropathologic evaluation using CERAD diagnostic criteria (29) and neuropathologic findings of senile plaques, Lewy bodies, and NFTs. The AD + LBD cases met neuropathologic criteria for AD and had concomitant Lewy bodies in cortical areas (30) . Both DLB and PD were pathologically categorized into LBD and assigned a specific LBD type (diffuse, transitional, or brainstem) based on the DLB consortium (31) . We examined the following regions reported to have prominent tau and/or >-synuclein pathology, including the hippocampus, basal nucleus of Meynert, substantia nigra, superior temporal gyrus, and motor cortex. Braak's NFT staging was assessed in all the cases examined (32).
Antibodies
We used the following antibodies as listed in 
Tau Fractions and Immunoblot Analysis
Fractions enriched in PHFs were isolated from AD brains according to our established protocol using zwitterionic detergent, sarcosyl (Sigma, St. Louis, MO) (33) . In this protocol, sarcosyl-insoluble pellets enriched in PHFs were suspended in 50 mM Tris/HCl buffer, pH 7.2, for biochemical and ultrastructural analyses. Brain tissue homogenates for Western blotting were obtained from frontal lobes of AD and control brains using urea buffer (8 M urea, 50 mM TrisHCl, pH 7.5, 1 mM EGTA). Recombinant human tau was expressed in Escherichia coli BL21 using an expression plasmid pRK172 containing a tau cDNA (clone htau40) and purified as previously described (34) . Clone htau40 (a generous gift of Michael Goedert) encodes the longest human tau isoform of 441 amino acid residues. Preparation of fetal human tau was obtained as described (35) . Brain homogenates and tau preparations were subjected to 10% SDSpolyacrylamide gel electrophoresis followed by electrotransfer onto nitrocellulose membrane. The membranes were incubated in a blocking medium containing 5% fat free milk (Carnation) in Tris-buffered saline (25 mmol/L Tris, 150 mmol/L NaCl, pH 7.4) for 30 minutes and then with primary antibodies overnight at 4-C. The membranes were subsequently incubated with horseradish peroxidaseY conjugated goat antirabbit/mouse secondary antibodies (Santa Cruz Biotechnology) at 1:1,000. After washing off the unbound antibodies, the blots were developed with enhanced chemiluminescence plus reagents (Amersham Pharmacia Biotech, Uppsala, Sweden) and exposed to Kodak x-ray film.
Frozen Brain Sections
Frozen brain samples from AD (temporal and occipital cortices) and PSP (frontal cortex and caudate nucleus) stored at Y80-C were transferred to Y20-C overnight then 4-C for 3 hours and cut into blocks. The blocks were incubated with fixatives (2% paraformaldehyde, 0.2% glutaraldehyde, 0.02% NP-40) for 30 minutes and washed with 0.1 mol/L phosphate-buffered saline (PBS, pH 7.4). The washed blocks were consecutively transferred to 10%, 20%, and 30% sucrose in PBS at 4-C for 1 hour each for cryoprotection. Frozen brains were cut into 10-to 15-Km-thick sections to perform immunofluorescence.
Immunohistochemistry and Immunofluorescence
Paraffin-embedded postmortem brains were serially cut into 8-Km-thick sections. Sections on slides were deparaffinized and dehydrated as reported previously (22, 33) . For some studies involving GRK2, GRK5, and Akt, selected sections were further treated with formic acid (95%, 30 minutes) (36) and/or microwaved for 15 minutes in 10 mmol/L citric acid buffer (pH 6.0). All sections were incubated in 0.3% hydrogen peroxide in PBS (30 minutes) then 5% goat serum blocking solution (30 minutes) followed by incubation with primary antibodies (overnight, 4-C). Sections were washed 3 times in PBS, incubated for 2 hours with biotin-conjugated goat anti-mouse/rabbit secondary antibody (1:200, Vector ABC Elite kit; Vector Laboratories, Burlingame, CA) and avidinYbiotinYhorseradish peroxidase complex for 2 hours. Horseradish peroxidase complexes (49) bound to specific antigens were detected with 0.3 mg/mL 3, 3 ¶-diaminobenzidine and 0.03% hydrogen peroxide. Sections were counterstained with hematoxylin, if needed, mounted, and observed with an Olympus microscope (Olympus, Tokyo, Japan). Images were captured with Bioquant software (Bioquant Image Analysis Corp., Nashville, TN). The relative abundance of immunostained structures was estimated from Y (absent) to +++ (frequent) if more than 90% was strongly immunolabeled (Table 3) . For double immunofluorescence study, deparaffinized and rehydrated sections or fixed frozen sections after cryoprotection were incubated overnight in a cocktail of anti-GRK2 either with PHF-1 or thioflavin S. After washing with PBS, sections were incubated in the mixture of Alexa fluor 488 (green)-and 594 (red)-conjugated secondary antibodies (1:200; Molecular Probes, Eugene, OR) for 2 hours at room temperature. To block the lipofuscin-like autofluorescence, 0.3% Sudan Black B in 70% ethanol was applied for 10 minutes (37). Sections were washed 3 times and mounted with aquamount (Lerner Laboratories, Pittsburgh, PA) containing 0.1% 4 ¶,6-diamidino-2-phenylindole (DAPI; Sigma) for nuclear staining. Sections were observed using Apotome microscope with axiovision software (Carl Zeiss AG, Germany).
Thioflavin S Staining of Neurofibrillary Tangles
Frozen brain sections were fixed with 2% parformaldehyde/0.2% glutaraldehyde/0.02% NP-40 for 30 minutes and stained with 0.01% thioflavin S in 10% formalin/PBS for 10 minutes. After washing with PBS, slides were mounted in aqueous Permount containing 0.1% DAPI and coverslipped for microscopic observation.
Immunoelectron Microscopy
Samples enriched in PHFs were deposited on grids (200 mesh copper, formvar-and carbon-coated) for 5 minutes followed by washing with PBS. Grids were subsequently incubated with the blocking solution containing 5% horse serum in PBS for 10 minutes and then with primary antibodies for 1 hour. Secondary antibodies were conjugated to 5-nm or 10-nm immunogold particles (Amersham) and applied at 1:50 dilution in PBS for 1 hour. Finally, the samples were stained with 2% (w/v) uranyl acetate solution for 2 to 5 minutes. Washed and air-dried grids were viewed using a Hitachi H7000 Transmission Electron Microscope and electron micrographs were digitally recorded.
RESULTS
Absence of GRK2 and Akt in Lewy Bodies and Lewy Neurites in Lewy Body Disease
We explored substantia nigra of LBD brains to determine whether GRKs colocalize with >-synuclein in classic Lewy bodies. Lewy bodies in melanin-containing neurons were identified by immunolabeling for total >-synuclein (Fig. 1A) and pS129syn (Fig. 1B) . We found that Lewy bodies were not immunolabeled for GRK2 (Fig. 1C, D) or GRK5 (Fig. 1E ). They were also negative for the active form of Akt (Fig. 1F) . Similar staining pattern was observed in >-synuclein deposits in serial sections from LBD brains. We found that Lewy neurites in hippocampal CA2Y3 (Fig. 2C ) and cortical Lewy bodies in subiculum (Fig. 2G) were immunolabeled for pS129syn, but showed no GRK2 immunoreactivity (Fig. 2D, H) . In comparison, NFTs in parahippocampal cortex as detected with pS214tau (Fig. 2K , arrows) were immunoreactive for GRK2 (Fig. 2L, arrows) . None of the parallel sections from control brains showed any structures labeled for GRK2 and other antigens studied (Fig. 2, control) . Our results suggested that NFTs, but not Lewy bodies or Lewy neurites, might contain GRK2.
Immunohistochemical Analysis of GRK2 in Neurofibrillary Tangles From Alzheimer Disease + Lewy Body Disease Brain
To confirm the colocalization of GRK2 with deposits of fibrillary tau rather than >-synuclein, we examined CA2Y3, subiculum, and parahippocampal gyrus in AD + LBD brains. Neurofibrillary pathology is usually prominent in these regions and occasionally overlaps with >-synuclein deposits. Serial sections of the hippocampus staining with pS129syn disclosed Lewy neurites (Fig. 3A, arrow) and Lewy bodies (Fig. 3D, arrows) . Staining with pS214tau identified NFTs, pretangles (Fig. 3C, arrows) , and neuritic plaques (Fig. 3C, asterisks) . GRK2 immunoreactivity was associated with NFTs in pyramidal neurons, especially in the parahippocampal cortex (Fig. 3E , arrows) and subiculum (Fig. 3H, arrows) . However, it was not associated with pS214tau-positive pretangles (Fig. 3B vs. 3C, arrows) and neuritic plaques (Fig. 3B vs. 3C, asterisks) . Moreover, GRK2 immunoreactivity was absent in Lewy neurites (Fig. 3A vs. 3B, arrow) and Lewy bodies (Fig. 3D vs. 3E ).
Both GRK2 and Akt Localized with Tau Inclusions in Alzheimer Disease and Progressive Supranuclear Palsy
To characterize GRK2 and GRK5 immunoreactivity in neurofibrillary inclusions, we examined the hippocampal region and amygdala in AD brains. In addition to GRKs, we were also interested in Akt reported to associate with tau lesions (26, 27) . All sections were pretreated with 95% formic acid for 30 minutes. The treatment enhanced GRK2 immunoreactivity in all tau inclusions in paraffin-embedded brain sections. Hippocampal CA1 region contained numerous NFTs and neuritic threads as detected using phospho-tau (CP13) labeling (Fig. 4A) . Some, but not all, NFTs were also positive for GRK2 (Fig. 4B vs. 4A ), but neuritic threads (Fig. 4E , arrow) were rarely labeled (Fig. 4F) . Based on Â20 field cell count, approximately 40% to 50% of all NFTs detected with CP13 in hippocampal lesions were GRK2-positive (Fig. 4A  vs. 4B, C) . No NFTs, however, were positive for GRK5 (Fig.  4D) . Like in the hippocampal CA1 region, amygdala contained phospho-tau (pS214 tau) -positive NFTs (not shown). NFTs in amygdala were immunoreactive for GRK2 (Fig. 4G) as well as the active form of Akt (Fig. 4H) . Extracellular tangles (Fig. 4I, arrow) and granulovacuolar degeneration (Fig. 4J, arrow) were not labeled for GRK2. Neuritic plaques containing dystrophic neurites displayed GRK2 immunoreactivity in most (Fig. 4F) but not all cases (Fig. 3B) .
PSP is one of few tauopathies characterized by the presence of fibrillary deposits of tau in both neuronal and glial cells (33, 38) . Deposits include neuronal NFTs and globose NFTs as well as tufted astrocytes and coiled bodies in oligodendrocytes. In the present studies, we examined the following PSP brain regions: hippocampus, caudate nucleus, accumbens, and hypothalamus. Like in AD, PSP sections were pretreated with 95% formic acid for 30 minutes. We identified several characteristic PSP inclusions that were positive for GRK2. They included tufted astrocytes in caudate (Fig. 5B) and accumbens (Fig. 5C ), coiled bodies in the hippocampus (Fig. 5F, G) , NFTs in the caudate nucleus (Fig. 5A) and hippocampus (Fig. 5H) , and globose NFTs in the hypothalamus (Fig. 5J) . Pretangles in neurons lacked the GRK2 staining. Tufted astrocytes were positive for pS214tau (Fig. 5D ). Coiled bodies (Fig. 5E) and NFTs (Fig. 5I) contained the active form of Akt (pThr308Akt).
These studies confirmed that GRK2, but not GRK5, was associated with neurofibrillary lesions in AD and PSP. The pattern of GRK2 staining in tau deposits was comparable to that of Akt in both neurons and glia.
GRK2 Localized With Pick Bodies in Pick Disease and Astrocytic Plaques in Corticobasal Degeneration
PiD and CBD have distinct tau pathologies composed of different tau isoforms. Whereas characteristic PiD lesions such as Pick bodies in neurons contain mainly tau isoforms expressing 3 repeats in the microtubule-binding domain (16) , CBD lesions are neuronal and glial and contain 4 repeat tau isoforms. We examined tau lesions in both disorders for a potential preference in GRK labeling. In PiD brain, the presence of abundant Pick bodies in the hippocampus was confirmed with phospho-tau (CP13) antibody (Fig. 6A ). They were mostly localized to granular cells in dentate gyrus, a region characteristic for its prominent Pick body pathology. We found that Pick bodies in this region were GRK2-positive (Fig. 6B) . A population of Pick bodies in motor cortex also displayed GRK2 immunoreactivity (data not shown). In CBD, unique pathologic structures are astrocytic plaques mainly composed of astrocytic processes containing abnormal tau deposits (38, 39) . We identified astrocytic plaques positive for phospho-tau (CP13) in the frontal cortex of CBD brain (Fig. 6C) . We found that some of the abnormal astrocytic processes in astrocytic plaques were immunolabeled for GRK2 (Fig. 6D) . In comparison, neuronal pretangles in basal nuclei of Meynert, which diffusely labeled for phospho-tau (CP13, Fig. 6E ), were mostly negative for GRK2 (Fig. 6F) . NFT-like neuronal inclusions in CBD are pleomorphic tangles often described as skein-like inclusions or argyrophilic filamentous tangles (38) . Fibrillary appearance differentiates pleomorphic tangles from pretangles. We found that pleomorphic tangles in CBD were positive for GRK2 (not shown). These findings confirmed our previous observations in AD + LBD that mature NFTs, but not pretangles, were more likely GRK2-immunoreactive (Fig. 3B vs. 3E ).
Our studies indicated that both PiD and CBD contained GRK2-positive tau inclusions. This suggested that GRK2 had no preferential binding to a specific tau isoform (3 or 4 repeats) or type of cell (neuronal or glial).
Colocalization of GRK2 and Tau in Intracellular Neurofibrillary Tangles and Isolated Paired Helical Filaments
To verify the localization of GRK2 in NFTs, we double-stained paraffin-embedded and frozen brain sections from AD brains with GRK2 and phospho-tau (PHF-1) antibodies using immunofluorescence. Apotome scanning images of neurons in subiculum showed that both GRK2 and PHF-1 staining merged (Fig. 7A-1) indicating a colocalization. This was confirmed by Apotome scanning of a double thioflavin S and GRK2 labeling (Fig. 7A-2 ). In addition, we found that although all GRK2-positive neurons were stained with thioflavin S, not all thioflavin S-positive neurons were stained for GRK2. The possibility that this was the result of granular autofluorescence of lipofuscin-burden neurons was minimized by Sudan Black B treatment suppressing autofluorescence (37). Our results suggested that GRK2 was associated with some, but not all NFTs. This finding confirmed our earlier results with CP13 and GRK2 staining (Fig. 4A, B) .
Ultrastructural study showed that filaments extracted from NFT-enriched regions in AD were 14-nm wide and mostly twisted at 80-nm intervals characteristic of PHFs in AD (33, 40) . By using double labeling with 5-nm and 10-nm immunogold particles, we found that isolated filaments were heavily colabeled with PHF-1 (5-nm gold particles) and GRK2 (10-nm gold particles) antibodies (Fig. 7B) . These studies suggested that GRK2 might tightly bind to tau filaments. Because filaments were obtained using sarcosyl extraction, we concluded that GRK2 binding was insensitive to sarcosyl.
GRK2 and Tau Do Not Crossreact
To minimize the possibility that labeling of PHFs by GRK2 was the result of crossreactivity between the anti-GRK2 antibody and PHF-tau polypeptides, we performed Western blot analysis. We found that Tau 46, a monoclonal antibody raised against total tau protein, bound 3 polypeptides of PHF-tau (60, 64, and 68 kD) in the AD brain, tau protein between 45 and 64 kD in the control brain, a recombinant of the longest human tau isoform (68 kD), and the 55-kD polypeptide of tau in human fetal tau preparations (Fig. 8A, bracket) . Unlike Tau 46, the anti-GRK2 antibody showed no binding to tau protein, but recognized a single band of approximately 80 kD corresponding to the molecular size of GRK2 polypeptide (Fig. 8B) . The 80-kD polypeptide was detected in homogenates from AD and control brains, but not preparations of recombinant or fetal tau. In the brain homogenates, we also detected a trace of smaller size polypeptide (approximately 70 kD) that could correspond to a GRK2 degradation product. These findings indicate that labeling of PHFs by anti-GRK2 antibody was the result of GRK2 tightly bound to filaments rather than crossreactivity with PHF-tau polypeptides.
DISCUSSION
We found that GRK2 was associated with a majority of tau lesions but not with >-synuclein deposits in several neurodegenerative disorders. GRK2-positive lesions were detected in both neuronal and glial cells (Table 3) . Among neuronal inclusions, NFTs, and globose tangles, but not pretangles or extracellular tangles, were GRK2-positive. Astroglial inclusions containing GRK2 were tufted astrocytes and astrocytic plaques, whereas oligodendroglial inclusions were coiled bodies. GRK2-positive lesions contained 3-repeat tau (PiD), 4-repeat tau (PSP and CBD), or both (AD). Our studies suggest that association of GRK2 with tau lesions is universal in nature and is unrelated to any specific isoform of tau.
GRK2 is widely distributed in neurons throughout the central nervous system in the normal rat brain. It is present in both postsynaptic densities and presynaptic axon terminals consistent with a general role of GRK2 in the desensitization of synaptic receptors (41, 42) . Our present studies also showed abundant immunoreactivity of GRK2 polypeptide (approximately 80 kD) in control and AD brain samples by Western blotting. By immunohistochemistry, however, we found very little GRK2 immunoreactivity associated with structures other than abnormal tau deposits. The absence of GRK2 immunoreactivity in control tissue sections is likely to be the result of other factors than postmortem instability reported for GRK2 in animal (43) and human brains (44) . Some of these factors may be related to solubility of GRK2 or antigen blockage. Studies of other brain proteins such as tau encountered similar difficulties in antigenic detection by immunohistochemistry (45) .
Our present studies showed that GRK2 immunoreactivity was associated with fibrillary lesions rather than pretangles. Moreover, only 40% to 50% of NFTs were GRK2-positive. These data suggest that GRK2 may preferably accumulate in mature NFTs. Alternatively, the amount of GRK2 in pretangles could be below the detection level in our studies. In contrast to NFTs, neuropil threads containing fibrillary tau showed very little or no GRK2 immunoreactivity. Differential deposition of GRK2 is likely to be the result of factors other than maturation because neuropil threads accumulate at early stages of neurofibrillary pathology (46) . One of these factors could be a different subcellular localization of neuropil threads (axonal) and NFTs (perinuclear). For example, association of GRK2 with NFTs may be induced by an abnormal increase in cytosolic GRK2 as a result of translocation of GRK2 from the membrane to the cytosolic compartments. In normal human brains, 60% of GRK2 is localized in cytosol and 40% in the membrane fraction (44) . Recent studies of transgenic mouse model of AD have shown that GRK2 content is upregulated in the cytosol and reduced in the membrane fraction at early stages of the AD-like pathology (47) . Translocation studies of GRK2 in AD and other tauopathies have yet to be performed.
We postulate that GRK2 binds to NFTs in a specific manner because 1) GRKs and tau share no structural similarity to account for antibody crossreactivity, 2) our GRK2 antibody shows no crossreactivity with tau by Western blotting, and 3) control brains show no GRK2-immunoreactive structures. On the other hand, GRK2 binds to and effectively phosphorylates the cytoskeletal protein tubulin (9) , which has been shown to be present in NFTs (48) . This alternative, however, is less plausible because GRK2 binds to isolated PHFs, which contain very little tubulin (9, 49) .
Although several studies reported that GRK2 and GRK5 phosphorylate >-synuclein at Ser129, a phosphoepitope associated with the fibrillary form of >-synuclein, our data showed no evidence of GRK2 and GRK5 immunoreactivity in >-synuclein inclusions in LBD brains. This was not the result of the absence of pS129syn immunoreactivity in Lewy bodies or Lewy neurites as tested with the phospho-specific antibody. It is possible that other kinases such as casein kinase 1 and 2 (14) play a more significant role in phosphorylation of >-synuclein in vivo or in pathologic conditions.
Recent evidence suggests that cell surface receptors that transmit signals through GPCRs stimulate Akt activity in a tyrosine-phosphorylation independent process (50) . The presence of GRK2 and Akt, 2 kinases involved in G-protein signaling in abnormal tau aggregates (28, 51) , strongly suggests their role in tauopathies. In addition to Akt, other protein kinases were also identified in NFTs and their role in phosphorylation of specific sites in tau indicated. They include glycogen synthase kinase-3 (52), cdk5/p25, c-Jun aminoterminal kinase, extracellular signal-regulated protein kinases, mitogen-activated protein kinase, p38 (53) , and lipid raft-associated Fyn (54) among others. Results of the present studies suggest that GRK2 could be a novel kinase of tau and could play a role in tau hyperphosphorylation. Further studies are needed to confirm the potential role of GRK2 in fibrillary pathology of tau in neurodegenerative disorders.
